FDA Approves Cephalon’s CLL Therapy Treanda With Broad Label
Executive Summary
A broad label for Cephalon's Treanda could increase the sales potential for the chronic lymphocytic leukemia therapy, which can be used across multiple lines of treatment and as monotherapy or in combination regimens
You may also be interested in...
Cephalon’s Treanda Approved For Indolent Non-Hodgkin’s Lymphoma
Firm says convenient dosing schedule is a plus for the drug, though it will be combined – not competing – with other NHL chemotherapy agents.
FTC Sues Cephalon For Anticompetitive Side Deals In Reverse Settlements
The Federal Trade Commission is once again challenging reverse settlements between a brand name company and its would-be generic competitors. This time around, the agency is focusing on side deals tacked onto the settlements, contending they constitute unfair competition
The Year Ahead: Controversial NDAs Could Entangle FDA In ‘08; Where Are The Oncologics?
Looking ahead at FDA's review calendar for 2008, the agency will be wrestling with several enigmatic decisions as it considers applications for fibromyalgia and chronic fatigue syndrome, controversial diseases with nebulous definitions and diagnoses